Aurora Cannabis Inc. (TSX: ACB, NASDAQ: ACB), a leading Canadian medical cannabis company, has urged its shareholders to reject an unsolicited takeover bid from Curaleaf Holdings, Inc. (TSX: CURA, OTCQX: CURLF). The board of directors, following a comprehensive review and advice from financial and legal advisors, unanimously concluded that the hostile bid is not in the best interests of Aurora or its shareholders. The company stated that the offer, valued at approximately $272 million, significantly undervalues Aurora and exposes its shareholders to substantial risks.
Miguel Martin, Executive Chairman and CEO of Aurora, emphasized that the transaction would be harmful to Aurora shareholders. He highlighted that Curaleaf carries over $1 billion in debt, while Aurora is debt-free with approximately $149 million in cash. Martin accused Curaleaf of attempting to use Aurora shareholders' cash to improve its own balance sheet and acquire Aurora's assets at a discount. He also warned that the bid offers intentionally limited upside, does not reflect Aurora's fundamental value, and would leave Aurora shareholders with limited voting influence in a combined company.
Aurora's board advised shareholders to "REJECT the Hostile Bid by TAKING NO ACTION and NOT TENDERING their shares." They argued that the bid does not adequately reflect Aurora's leadership in medical cannabis, balance sheet flexibility, international expertise, or long-term growth potential. Independent equity research analysts, including TD Securities Inc. – Canada, have also echoed the sentiment that the hostile bid undervalues Aurora. The company maintains that it has a stronger path forward and significant value creation ahead by continuing its current strategy as a global, high-margin medical cannabis leader.
